Admon

Arie Admon

Education/ Resume:

B.Sc. Agronomy, 1976, Hebrew University, Rehovot, Israel

M.Sc. Plant physiology and biochemistry, 1980, Hebrew University, Rehovot, Israel

Ph.D. Biochemistry, 1984, Weizmann Institute, Rehovot, Israel

Post doctorate #1: Biochemistry and biophysics, 1986, Chemistry Department, Cornel University, Ithaca, NY

Post Doctorate #2: Biochemistry and cell biology. 1987, Cold Spring Harbor Lab, Cold Spring Harbor, NY

Senior Research Associate, 1993, Howard Hughes Medical Institute, Department of Molecular & Cell Biology, U.C. Berkeley, Berkeley, CA

Associate Professor, 2012, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel

Full professor, 2019, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel

Professor Emeritus, 2019- date, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel

read more
Research Summary

My main research interest focuses on molecular immunology, with a special interest HLA-peptidomics; the research field aimed at characterization of the full repertoires of HLA peptides presented by human cells (HLA peptidome) and the implementation of the HLA peptidomics into development of personalized immunotherapy of cancer, autoimmunity, and inflammatory diseases.

These research directions rely heavily on the use of the modern tools of peptidomics and proteomics, especially mass spectrometry and bioinformatics. My basic research interests focus on the issue of the molecular and cellular mechanism of the antigen processing and presentation. I am also the academic head the Technion’s Smoler Proteomics Center.

read more
Key Publications
  • Rijensky, N. M., Blondheim Shraga, N. R., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N., Perry, D., Rubin, E., Haviv, I., and Admon, A. (2020) Identification of tumor antigens in the HLA peptidome of patient-derived xenograft tumors in mouse. Mol. Cell. Proteomics 19, mcp.RA119.001876
  • Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P.-Y. Y., Dutoit, V., Wick, W., Platten, M., Winkler, F., Von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, U., Ottensmeier, C., Van Der Burg, S. H., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., and Admon, A. (2019) Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol. Cell. Proteomics 18, 1255–1268
  • Rijensky, N. M., Blondheim Shraga, N. R., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N., Perry, D., Rubin, E., Haviv, I., and Admon, A. (2020) Identification of tumor antigens in the HLA peptidome of patient-derived xenograft tumors in mouse. Mol. Cell. Proteomics 19, mcp.RA119.001876
  • Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P.-Y. Y., Dutoit, V., Wick, W., Platten, M., Winkler, F., Von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, U., Ottensmeier, C., Van Der Burg, S. H., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., and Admon, A. (2019) Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol. Cell. Proteomics 18, 1255–1268
  • Komov, L., Kadosh, D. M., Barnea, E., Milner, E., Hendler, A., and Admon, A. (2018) Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive “Empty” Molecules Rather than by the Supply of Peptide Ligands. Proteomics 18, e1700248
  • Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A., and Samuels, Y. (2016) Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110–7
  • Milner, E., Gutter-Kapon, L., Bassani-Strenberg, M., Barnea, E., Beer, I., and Admon, A. (2013) The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome. Mol. Cell. Proteomics 12, 1853–64
  • Admon, A., and Bassani-Sternberg, M. (2011) The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing. Mol. Cell. Proteomics 10, O111.011833
  • Bassani-Sternberg, M., Barnea, E., Beer, I., Avivi, I., Katz, T., and Admon, A. (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A 107, 18769–18776
  • Ben Dror, L., Barnea, E., Beer, I., Mann, M., and Admon, A. (2010) The HLA-B*2705 peptidome. Arthritis Rheum. 62, 420–9
  • Milner, E., Barnea, E., Beer, I., and Admon, A. (2006) The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol. Cell. Proteomics 5, 357–65
  • Admon, A., Barnea, E., and Ziv, T. (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2, 388–98
  • Buchsbaum, S., Barnea, E., Dassau, L., Beer, I., Milner, E., and Admon, A. (2003) Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics 55, 172–176
  • Barnea, E., Beer, I., Patoka, R., Ziv, T., Kessler, O., Tzehoval, E., Eisenbach, L., Zavazava, N., and Admon, A. (2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32, 213–22
read more
Recent Publications
  • Bai, C., Tesker, M., Melamed-Kadosh, D., Engelberg, D., and Admon, A. (2020) Hog1-induced transcription of RTC3 and HSP12 is robust and occurs in cells lacking Msn2, Msn4, Hot1 and Sko1. PLoS One 15, e0237540
  • Rijensky, N. M., Blondheim Shraga, N. R., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N., Perry, D., Rubin, E., Haviv, I., and Admon, A. (2020) Identification of tumor antigens in the HLA peptidome of patient-derived xenograft tumors in mouse. Mol. Cell. Proteomics 19, mcp.RA119.001876
  • Yair-Sabag, S., Tedeschi, V., Vitulano, C., Barnea, E., Glaser, F., Melamed Kadosh, D., Taurog, J. D. J. D., Fiorillo, M. T. M. T., Sorrentino, R., and Admon, A. (2018) The Peptide Repertoire of HLA-B27 may include Ligands with Lysine at P2 Anchor Position. Proteomics 18, e1700249
  • Komov, L., Kadosh, D. M., Barnea, E., Milner, E., Hendler, A., and Admon, A. (2018) Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive “Empty” Molecules Rather than by the Supply of Peptide Ligands. Proteomics 18, e1700248
read more
Also available to you on social media
Font Resize
Contrast